What is the mechanism of action of Anamorelin? Is it a receptor agonist?

Anamorelin is an oral small molecule drug, mainly used to treat cancer-related cachexia (cancer cachexia), especially in patients with advanced non-small cell lung cancer and has good clinical application prospects. Its mechanism of action is closely related to the release of growth hormone. It is a ghrelin (ghrelin) receptor agonist that can simulate the physiological effects of natural ghrelin, thereby improving the patient's appetite, weight and nutritional status.

Specifically, anamorelin activates the growth hormone secretory peptide receptor 1a (GHS-R1a), prompting the hypothalamus-pituitary system to release growth hormone ( GH), which in turn promotes the liver to secrete insulin-like growth factor-1 (IGF-1). These hormones work together to help enhance muscle synthesis and reduce muscle breakdown, thereby improving the weight loss and muscle loss problems of cancer patients caused by metabolic disorders. At the same time, it also has the effect of stimulating the appetite center, increasing the patient's appetite and food intake, and helping to restore physical fitness and quality of life.

Unlike traditional methods such as direct nutritional supplementation or the use of steroids, anamorelin fundamentally improves energy intake and muscle metabolism by simulating endogenous hormone signaling pathways with relatively few side effects. Therefore, it is regarded as a new targeted drug for the treatment of cancer cachexia. It is worth noting that it does not belong to the steroid or erythropoietin drugs and is suitable for cancer patients who have lost significant weight but still have certain basic physical fitness.

In general, anamorelin, as a ghrelin receptor agonist, increases growth hormone andIGF-1 levels through endocrine regulation mechanisms, indirectly promoting appetite, weight gain, and muscle synthesis. This mechanism not only provides a new treatment idea for cachexia, but also benefits patients in maintaining nutritional status and improving quality of life, and is especially suitable for the management of tumor-related chronic wasting diseases.

Reference materials:https://pmc.ncbi.nlm.nih.gov/articles/PMC4677053/